New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs), are central to the maintenance treatment of patients with COPD...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Urzo, Anthony D, Cazzola, Mario, Hanania, Nicola A, Buhl, Roland, Maleki-Yazdi, M Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135066/
https://www.ncbi.nlm.nih.gov/pubmed/30233171
http://dx.doi.org/10.2147/COPD.S113306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135066/
https://www.ncbi.nlm.nih.gov/pubmed/30233171
http://dx.doi.org/10.2147/COPD.S113306

Ejemplares similares